AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04173143 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Craniocervical flexion training without pressure biofeedback
Description: Total 15 patients participated in this control group.Session was given 3 times in a week. Each session continue forapproximately 20 minutes. The patient lies in supine crook lying position. The patientwas maximally retracted the chin and asked to maintained it while the patient lifts the head and neck until the head is relatively 2 to 5 cm (1 inch) abovethe couch. The examiner places a hand under the head of patient on the table. Patients were instructed to perform10 repetitions for a hold of 20 seconds initially, increasing it by 10 seconds progressively.The entire session had a maximum of 4 sets. Patient will be re-assessed for all baseline variables after 4 weeks of training
Study NCT00735371 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LDX 30 mg
Description: Eligible subjects will be randomized in a 1:1:1:1 ratio to a daily morning dose of LDX (30, 50, or 70mg/day) or placebo for a double-blind stepwise forced dose titration (3 weeks) followed by a 1-week Dose Maintenance Period. The test product is LDX, available in 30, 50, and 70mg capsules. All test products will appear identical to placebo to protect the study blind.
Study NCT00735371 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LDX 50 mg
Description: Eligible subjects will be randomized in a 1:1:1:1 ratio to a daily morning dose of LDX (30, 50, or 70mg/day) or placebo for a double-blind stepwise forced dose titration (3 weeks) followed by a 1-week Dose Maintenance Period. The test product is LDX, available in 30, 50, and 70mg capsules. All test products will appear identical to placebo to protect the study blind.
Study NCT00735371 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LDX 70 mg
Description: Eligible subjects will be randomized in a 1:1:1:1 ratio to a daily morning dose of LDX (30, 50, or 70mg/day) or placebo for a double-blind stepwise forced dose titration (3 weeks) followed by a 1-week Dose Maintenance Period. The test product is LDX, available in 30, 50, and 70mg capsules. All test products will appear identical to placebo to protect the study blind.
Study NCT00735371 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be identical to test product.
Study NCT03582488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-Flortaucipir
Description: Radioligands for PET imaging of beta-amyloid and neurofibrillary tangle tau pathology
Study NCT00395239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: inhaled corticosteroid
Description: Fluticasone; Budesonide; Ciclesonide Dosage and frequency is patient dependant.
Study NCT05665257 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training
Study NCT05665257 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Mini-PEP
Study NCT02352831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tosedostat
Study NCT02352831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Study NCT02352831 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fresh tissue biopsy
Description: Patients who have a partial response at the end of cycle 2 will be required to undergo biopsy if deemed safe for the patient and tissue is feasible to obtain.
Study NCT03494452 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: There is no intervention in this cross-sectional study
Study NCT03531086 — intervention group
Intervention type: DRUG
Intervention: Ioflupane I 123
Description: Ioflupane I 123 will be administered IV push prior to SPECT imaging
Study NCT01526213 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Fexofenadine
Description: This randomized, open-label, single-dose, 3-way crossover study in healthy volunteers will be conducted in the CTRC. Once subjects are identified as eligible to participate, based on their screening evaluation and according to inclusion/exclusion criteria, they will undergo 3 phases. By randomized crossover design, the subject will receive fexofenadine with water, grapefruit juice, or furanocoumarin-free grapefruit juice.
Study NCT03738046 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: Group therapy will occur once weekly (60-90-minute sessions) at the HOPE TEAM offices for 24 weeks. The group sessions with consist of 4 skill modules, each of which last 6 sessions. Three of these--the Cognitive, Social Skills, and Problem-Solving Modules-will be modules taken from Cognitive and Behavioral Social Skills Training (CBSST; Granholm McQuaid, \& Holden, 2016) and modified for use with CHR adolescents. The fourth module-Stress Coping-will be adapted for this sample from an established group CBT treatment for psychosis (Lecomte, Leclerc, \& Wykes, 2016).
Study NCT00124917 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Areas of pathologically confirmed malignancy will undergo dose escalation as described below. Areas of image abnormality that could not be biopsied or were without definite pathologic evidence of malignancy will be given intermediate doses. The remainder of the prostate gland will receive standard dose (as per the Radiation Therapy Oncology Group (RTOG) 9406 study) 7560 centigray (cGy) in 180 cGy daily fractions.\[1\]
Study NCT03648229 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Selective laser trabeculoplasty (SLT)
Description: Delivery of laser energy to the trabecular meshwork of the eye with the goal of reducing intraocular pressure
Study NCT03648229 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Latanoprost ophthalmic solution
Description: Prostaglandin analogue topical ophthalmic medication for reduction of intraocular pressure
Study NCT00061893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: celecoxib
Description: Given orally, Celecoxib 250 mg/m2 PO BID (500mg/m2/day) from Day 1 of Cycle 1 through Day 21 of Cycle 14. The dose should be rounded off to the nearest 100 mg. If PK studies are being done, Celecoxib should be given 24 hours prior to the other drugs for Cycle 1 only. \[Celecoxib may be interrupted for up to 7 days around the time of surgical procedures.\] .
Study NCT03648229 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Timolol ophthalmic solution
Description: Timolol ophthalmic solution 0.5% for reduction of intraocular pressure
Study NCT01176513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GE-148 (18F)
Description: All subjects will receive an i.v. dose of GE-148 (18F) Injection at 10 mCi (370 MBq) to provide adequate image quality throughout the specified imaging period.
Study NCT04107324 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ARAPS
Description: In a previous experimental study on rats, the investigators have shown that PVE combined with radiofrequency ablation (RFA), hereafter called Associated Radiofrequency Ablation and Portal Vein Ligation for Staged Hepatectomy (ARAPS), can induce accelerated growth of the FLR
Study NCT04107324 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: PVE
Description: Portal vein embolisation
Study NCT04119362 — intervention group
Intervention type: OTHER
Intervention: Quality of live questionnaires
Description: EORTC-Q30 questionnaire, additonal questionnaire on worries about quality of life impairments and on physical condition every 8 weeks. No additional visits will be carried out for questionnaires. Questionnaires will be handed out to patients during routine visits.
Study NCT00061893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV, 1200 mg/m2 IV infusion over 1 hour with MESNA uroprotection, on Day 1. For children \< 1 year treat with 50% doses calculated on a m2 basis. If tolerated (no delay in administration of the next cycle due to delayed count recovery or delayed resolution of other toxicities and no serious toxicities), consider increasing to 75% and then to 100% of the calculated full dose.
Study NCT00061893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV, Doxorubicin 75 mg/ m2 /course continuous IV infusion over 48 hours, beginning Day 1. Note: The total doxorubicin dose per cycle is 75 mg/ m2, which will be given as 37.5 mg/m2/day x 2 days. Doxorubicin may be given as a continuous infusion or brief infusion.
Study NCT00061893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV, Vincristine 2 mg/m2 IV push, on Day 1. Maximum dose 2 mg. For children \< 1 year treat with 50% doses calculated on a m2 basis. If tolerated (no delay in administration of the next cycle due to delayed count recovery or delayed resolution of other toxicities and no serious toxicities), consider increasing to 75% and then to 100% of the calculated full dose.
Study NCT00061893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ifosfamide
Description: Given IV,Ifosfamide 1800 mg/m2 /day IV infusion over 1 hour, Days 1-5 of each cycle. (9,000 mg/m2 max total dose per cycle). Prehydrate for 6 hours, 1,000 ml/m2 total volume (165 ml/m2/hour for 6 hours). For children \< 1 year treat with 50% doses calculated on a m2 basis. If tolerated (no delay in administration of the next cycle due to delayed count recovery or delayed resolution of other toxicities and no serious toxicities), consider increasing to 75% and then to 100% of the calculated full dose.
Study NCT00061893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinblastine sulfate
Description: Given IV, Vinblastine 1 mg/m2/d IV push three times per week beginning Day 1 of Cycle 1 and continuing through Day 21 of Cycle 14. In weeks during which vincristine is given, hold one dose of vinblastine and administer only 2 doses of vinblastine during that week. If vinblastine is due the same day as vincristine, hold that dose of vinblastine. \[Vinblastine may be interrupted for up to 7 days around the time of surgical procedures.\]
Study NCT00061893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV, Vincristine 2 mg/m2 IV push, on Day 1. Maximum dose 2 mg. For children \< 1 year treat with 50% doses calculated on a m2 basis. If tolerated (no delay in administration of the next cycle due to delayed count recovery or delayed resolution of other toxicities and no serious toxicities), consider increasing to 75% and then to 100% of the calculated full dose.
Study NCT00061893 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Description: Patients who respond to induction chemotherapy undergo surgery on week 13. Patients who have inadequate margins after surgery undergo radiotherapy beginning on week 15. (see Detailed Description for frequency of administration and groups evaluated)
Study NCT00061893 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Patients with unresectable lesions undergo radiotherapy 5 days a week for approximately 6 weeks beginning on week 13. (see Detailed Description for frequency of administration and groups evaluated)
Study NCT00061893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MESNA
Description: The total daily MESNA dose is equal to at least 60% of the daily cyclophosphamide or ifosfamide dose, or by continuous infusion of the 60% dose. MESNA continuous infusion should be started at the same time as the cyclophosphamide/ifosfamide and be completed no sooner than 8 hours after the end of the cyclophosphamide or ifosfamide infusion. The oral dose of MESNA is 2x the IV dose. Patients able to tolerate oral MESNA may receive the final dose by mouth at 40% of the oxazaphosphorine (cyclophosphamide or ifosfamide) dose. The dose should be given two hours earlier than the IV dose would be given. Additionally, if the patient vomits within two hours after the oral dose, the dose should be repeated or IV MESNA given.
Study NCT00061893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: G-CSF (Filgrastim) 5 micrograms/kg/day subcutaneously beginning 24 to 48 hours after the last dose of chemotherapy, and continuing until the absolute neutrophil count is 2,000/µL or greater after nadir.
Study NCT04119180 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine 50 MG/ML
Description: Ketamine injectable solution in a concentration of 50.0 mg/mL via oral route; dose of 4.0 mg/kg maximum 100.0 mg
Study NCT04119180 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam Hcl 2Mg/Ml Syrup
Description: Midazolam oral solution in a concentration of 2.0 mg/mL via oral route; dose of 0.5 mg/kg, maximum 5.0 mg when associated with ketamine;
Study NCT04119180 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Protective stabilization
Description: The legal guardian or accompanying person appointed by the legal guardian should sit in the dental chair with the child and contain leg and arm movements. A dental assistant keeps the child's head contained during care.
Study NCT02753426 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Doxycycline
Description: Doxycycline 20mg capsule by mouth, twice a day for 30 days.
Study NCT02753426 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo (for Doxycycline)
Description: Inactive pill manufactured to mimic Doxycycline 20mg. Capsule by mouth, twice a for 30 days.
Study NCT02115295 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine
Description: Given IV
Study NCT02115295 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV
Study NCT02115295 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gilteritinib
Description: Given PO
Study NCT02115295 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin
Description: Given IV
Study NCT02115295 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02115295 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midostaurin
Description: Given PO
Study NCT02115295 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO
Study NCT03171337 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupuncture at acupoints for CTTH according to TCM theory using stainless filiform needle.
Study NCT03171337 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fu's Subcutaneous Needling (FSN)
Description: Fu's subcutaneous needling at specific points for CTTH using soft casing needle.
Study NCT04119362 — intervention group
Intervention type: OTHER
Intervention: Optional translational project
Description: Collection of archival tumor material for future translational projects. No biopsy will be performed in the context of this registry. Only tumor samples obtained in the context of standard of care and after explicit informed context will be used.
Study NCT02040805 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Cognitive Behavioral Therapy
Description: Group therapy over approximately 20 weeks, based on a structured manual adapted from the individual CBT workbook for hoarding by Steketee and Frost (2006). Each session will be 2 hours in length and consists of weekly check-ins, psychoeducation about hoarding, developing understanding and awareness of one's hoarding symptoms and patterns, behavior modification, cognitive restructuring, goal-setting, motivational enhancement, in vivo and imaginal exposure for discarding and acquisition, executive skills training (organization, sorting, planning, decision-making, problem-solving, etc.), guidelines on establishing clutter buddies, and relapse prevention. Groups will be led by clinical postdoctoral psychology fellows in the Department of Psychiatry at UCSF.
Study NCT02040805 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Facilitated Support Group
Description: Fifteen sessions of peer facilitated, group support, over the course of 20 weeks, based on a structured manualized approach (Buried in Treasures: Help for Compulsive Acquiring, Saving, and Hoarding). Each session will be 2 hours in length. In this model, two trained peers, usually, but not necessarily, with personal lived experience of hoarding, will guide the group chapter by chapter through the Buried in Treasures manual.
Study NCT02731716 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: New Payment Model
Description: Providers will no longer be paid based upon FFS, but on the new payment model, which includes PMPM and quality incentives.
Study NCT02731716 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Comparisons
Description: Providers will receive weekly emails showing comparisons in quality metrics and total cost of care. They will be compared to other providers in their provider organization.
Study NCT02731716 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A1c Member/Provider Incentive
Description: Attributed members and their PCPs will receive up to $75 for a reduction of a1c by 0.5% per quarter (2 quarters).
Study NCT04487782 — intervention group
Intervention type: OTHER
Intervention: Focus Groups
Description: The investigators are enrolling up to 56 women (total) to participate in semi-structured focus groups of 6-8 women per group conducted either in-person or virtually (online) to help us tailor a lifestyle intervention for midlife women during perimenopause.
Study NCT03846960 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: using specially adapted VNscope
Description: surfactant administration via thin catheter using a specially adapted VNscope
Study NCT03171337 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham acupuncture
Description: Sham acupuncture at non-acupoints using Steinberger placebo needles
Study NCT02442349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9291
Description: Once daily tablet 80 mg
Study NCT03109639 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional EUS FNA needle
Description: Participants randomised to Group A will undergo tissues acquisition using the Conventional EUS FNA needle and then crossed over to receive the experimental Acquire EUS- FNB device.
Study NCT03846960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: surfactant administration
Description: surfactant administration via thin catheter using a specially adapted VNscope
Study NCT01505686 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRI scan
Description: MRI scan with a 1,5 T MRI scanner
Study NCT03945812 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Granulocyte Colony Stimulating Factor
Description: Filgrastim, Amgen, California, USA 300 mg/1.0 mL
Study NCT01725204 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib + PegIFN
Study NCT03109639 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acquire FNB device
Description: Participants randomised to Group B will undergo tissue acquisition using the experimental Acquire EUS FNB device and then crossed over to receive the conventional EUS FNA needle
Study NCT00761462 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Description: Either as oral suspension, oral tablets or sequential intravenous (IV) - oral therapy or purely IV therapy according to label
Study NCT03602365 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gentle Jogger (GJ)
Description: Gentle jogger is a passive jogging device which passively moves the feet up and down simulating jogging
Study NCT03420547 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RISE
Description: Intervention will consist of 3 sessions over 6 weeks. Each session will last 2 hours and be conducted with a clinical psychologist or medical social worker. The intervention content include psycho-education, communication training between the couple, and exercises to foster intimacy. A therapy manual will be developed to ensure program delivery fidelity. A folder with session summaries will be provided to the participants.The intervention content include psycho-education, communication training between the couple, and exercises to foster intimacy. A therapy manual will be developed to ensure program delivery fidelity. A folder with session summaries will be provided to the participants.
Study NCT00452868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Description: Donepezil 5 milligrams a day for 6 weeks
Study NCT02949999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voclosporin
Study NCT00761462 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Non-quinolone antibiotic
Description: Common used dose and route
Study NCT00790270 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclobenzaprine
Description: 5 mg orally every 8 hours as needed
Study NCT00790270 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: Ibuprofen 400 mg every 8 hours as needed
Study NCT02949999 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Voclosporin
Study NCT00790270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen plus Cyclobenzaprine
Description: Ibuprofen 400 mg plus cyclobenzaprine 5 mg every 8 hours as needed
Study NCT00687739 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: leuprolide acetate
Description: 3.75 mg for depot suspension delivered by monthly intramuscular injection for 5 months
Study NCT00687739 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: leuprolide acetate
Description: 3.75 mg for depot suspension delivered by monthly intramuscular injection for 5 months
Study NCT00687739 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leuprolide acetate
Description: 3.75 mg for depot suspension delivered by monthly intramuscular injection for 5 months
Study NCT00687739 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol Transdermal
Description: 0.075 mg patch per day for 5 months